Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Jul;182(1):243-244.
doi: 10.1007/s10549-020-05674-7. Epub 2020 May 20.

Treatment options for patients with HR+/HER2- advanced breast cancer during the COVID-19 pandemic: dose reduction of ribociclib does not diminish efficacy

Joyce O'Shaughnessy  1   2
Affiliations
Comment

Treatment options for patients with HR+/HER2- advanced breast cancer during the COVID-19 pandemic: dose reduction of ribociclib does not diminish efficacy

Joyce O'Shaughnessy. Breast Cancer Res Treat. 2020 Jul.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Dr. O’Shaughnessy reports AbbVie Inc., Agendia, Amgen Biotechnology, AstraZeneca, Bristol-Myers Squibb, Celgene Corporation, Eisai, Genentech, Genomic Health, GRAIL, Immunomedics, Heron Therapeautics, Ipsen Biopharmaceuticals, Jounce Therapeutics, Lilly, Merck, Myriad, Novartis, Ondonate Therapeutics, Pfizer, Puma Biotechnology, Prime Oncology, Roche, Seattle Genetics, Syndax Pharmaceuticals.

Comment in

Comment on

References

    1. Deitz JR, Moran MS, Isakoff SJ, et al. Recommendations for prioritization, treatment and triage of breast cancer patients during the COVID-19 pandemic. Breast Cancer Res Treat. 2020 doi: 10.1007/s10549-020-05644-z. - DOI - PMC - PubMed
    1. Beck JT, Neven P, Sohn J, et al. Ribociclib treatment benefit in patients with advanced breast cancer with ≥1 dose reduction: Data from the MONALEESA-2, -3, and -7 trials. Cancer Res. 2019;79(4S):P6-18-06.
    1. NCCN Clinical Practice Guidelines in Oncology for Breast Cancer V.3.2020.